Hyperglycemia Aggravates Blood-Brain Barrier Disruption Following Diffuse Axonal Injury by Increasing the Levels of Inflammatory Mediators through the PPARγ/Caveolin-1/TLR4 Pathway

Inflammation. 2023 Feb;46(1):129-145. doi: 10.1007/s10753-022-01716-y. Epub 2022 Jul 20.

Abstract

Hyperglycemia aggravates brain damage after diffuse axonal injury (DAI), but the underlying mechanisms are not fully defined. In this study, we aimed to investigate a possible role for hyperglycemia in the disruption of blood-brain barrier (BBB) integrity in a rat model of DAI and the underlying mechanisms. Accordingly, 50% glucose was intraperitoneally injected after DAI to establish the hyperglycemia model. Hyperglycemia treatment aggravated neurological impairment and axonal injury, increased cell apoptosis and glial activation, and promoted the release of inflammatory factors, including TNF-α, IL-1β, and IL-6. It also exacerbated BBB disruption and decreased the expression of tight junction-associated proteins, including ZO-1, claudin-5, and occludin-1, whereas the PPARγ agonist rosiglitazone (RSG) had the opposite effects. An in vitro BBB model was established by a monolayer of human microvascular endothelial cells (HBMECs). Hyperglycemia induction worsened the loss of BBB integrity induced by oxygen and glucose deprivation (OGD) by increasing the release of inflammatory factors and decreasing the expression of tight junction-associated proteins. Hyperglycemia further reduced the expression of PPARγ and caveolin-1, which significantly decreased after DAI and OGD. Hyperglycemia also further increased the expression of toll-like receptor 4 (TLR4), which significantly increased after OGD. Subsequently, the PPARγ agonist RSG increased caveolin-1 expression and decreased TLR4 expression and inflammatory factor levels. In contrast, caveolin-1 siRNA abrogated the protective effects of RSG in the in vitro BBB model of hyperglycemia by increasing TLR4 and Myd88 expression and the levels of inflammatory factors, including TNF-α, IL-1β, and IL-6. Collectively, we demonstrated that hyperglycemia was involved in mediating secondary injury after DAI by disrupting BBB integrity by inducing inflammation through the PPARγ/caveolin-1/TLR4 pathway.

Keywords: blood–brain barrier; diffuse axonal injury.; hyperglycemia; peroxisome proliferator-activated receptor γ.

MeSH terms

  • Animals
  • Blood-Brain Barrier
  • Caveolin 1 / metabolism
  • Diffuse Axonal Injury*
  • Endothelial Cells / metabolism
  • Glucose / metabolism
  • Humans
  • Hyperglycemia* / metabolism
  • Inflammation Mediators / metabolism
  • Interleukin-6 / metabolism
  • Oxygen / metabolism
  • PPAR gamma / metabolism
  • Rats
  • Rosiglitazone / pharmacology
  • Tight Junction Proteins / metabolism
  • Toll-Like Receptor 4 / metabolism
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • PPAR gamma
  • Caveolin 1
  • Toll-Like Receptor 4
  • Tumor Necrosis Factor-alpha
  • Inflammation Mediators
  • Interleukin-6
  • Rosiglitazone
  • Tight Junction Proteins
  • Glucose
  • Oxygen
  • TLR4 protein, human
  • Tlr4 protein, rat